TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of “Hold” from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $134.50.

Several analysts have commented on the stock. Stifel Nicolaus raised their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Needham & Company LLC reduced their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. UBS Group reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a research note on Tuesday. Finally, TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research report on Wednesday.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $68.86 on Friday. The company has a 50-day moving average price of $75.04 and a 200-day moving average price of $108.23. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of 15.65 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the firm posted $0.70 EPS. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities analysts predict that TransMedics Group will post 1.92 EPS for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in shares of TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. grew its position in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the last quarter. Finally, M&T Bank Corp purchased a new stake in TransMedics Group during the 2nd quarter valued at about $209,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.